Top Markets
Coin of the day
Hepion Pharmaceuticals, Inc. Hepion Pharmaceuticals, Inc.

Hepion Pharmaceuticals, Inc.

HEPA
Rang in Aktien #39072
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is... Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Aktienkurs
$0.0568
Zuletzt synchronisiert: 2026-08-13
Marktkapitalisierung
$661.36K
Veränderung (1 Tag)
11.37%
Veränderung (1 Jahr)
-5.33%
Land
US
Handel Hepion Pharmaceuticals, Inc. (HEPA)

Kategorie

Aktien-Split-Historie für Hepion Pharmaceuticals, Inc. (HEPA)
Die Aktie Hepion Pharmaceuticals, Inc. (Symbol: HEPA) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 14, 2026 statt.
Eine HEPA-Aktie, die vor dem Aug 14, 2026 gekauft wurde, entspricht heute 0 HEPA-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
0 -
CH
0 -
KR
0 -
BE